ESR2 and urothelial carcinoma: p53‐like type was resistant to neoadjuvant chemotherapy agents (methotrexate, vincaleukoblastine, azithromycin, cisplatin, etc.), and all the chemoresistant bladder cancer showed p53‐like subtype after chemotherapy.29 In a TCGA analysis, urothelial carcinoma was divided into four genotypes: type I and type II cells have high expression of ERBB2 and activation of ESR2 pathway, whereas type I has FGFR3 mutation and a papillary morphology.